Group | Gemcitabine (n = 154) | Erlotinib (n = 155) |
---|---|---|
All patients | 76,625 | 184,733 |
Performance-status | ||
0 | 52,213 | 94,908 |
1 | 372,624 | –* |
Histology | ||
Adenocarcinoma | 62,292 | 97,160 |
Squamous cell carcinoma or unknown | 83,291 | –* |
Response to induction therapy | ||
Objective response | 64,296 | 101,186 |
Stable disease | 153,337 | –* |